NMBio MemberAgilvax

Agilvax develops targeted vaccines and immunotherapies for infectious diseases and cancer utilizing its proprietary virus-like particle (VLP) platform technology. Unlike alternative VLP platforms, the Agilvax technology platform allows for both the discovery and implementation of novel vaccines and immunotherapies through a unique affinity selection process (reverse vaccinology).

Agilvax’s technology will revolutionize the development and discovery of vaccines and immunotherapies and will ultimately improve the millions of lives that are impacted by infectious diseases and cancer throughout the globe.